Ellman M H, Hurwitz H, Thomas C, Kozloff M
Department of Medicine, Humana Hospital-Michael Reese, Chicago, IL.
J Rheumatol. 1991 Nov;18(11):1741-3.
We describe the occurrence of a lymphoma in a patient with rheumatoid arthritis (RA) taking weekly oral pulse methotrexate (MTX) in low doses for 33 months. This occurrence may be coincidental. There may be an increased incidence of lymphoma in RA not treated with immunosuppressive medications. However, the increasing use of MTX warrants reporting unusual events, especially malignancy. It is possible that even the mild immunosuppression that occurs with MTX therapy places patients with RA at added risk for developing lymphoproliferative diseases.
我们描述了一名类风湿关节炎（RA）患者在接受每周一次低剂量口服脉冲甲氨蝶呤（MTX）治疗33个月后发生淋巴瘤的情况。这种情况可能是巧合。在未接受免疫抑制药物治疗的RA患者中，淋巴瘤的发病率可能会增加。然而，MTX使用的增加使得报告异常事件变得必要，尤其是恶性肿瘤。即使是MTX治疗所产生的轻度免疫抑制也有可能使RA患者发生淋巴增殖性疾病的风险增加。
